Angion Biomedica Corp (ANGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANGN Stock Price Chart Interactive Chart >
ANGN Price/Volume Stats
| Current price | $1.50 | 52-week high | $16.04 |
| Prev. close | $1.32 | 52-week low | $1.08 |
| Day low | $1.31 | Volume | 199,900 |
| Day high | $1.56 | Avg. volume | 95,189 |
| 50-day MA | $1.69 | Dividend yield | N/A |
| 200-day MA | $4.41 | Market Cap | 44.94M |
Angion Biomedica Corp (ANGN) Company Bio
Angion Biomedica Corp. operates as a late-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica serves customers in the State of New York.
Latest ANGN News From Around the Web
Below are the latest news stories about Angion Biomedica Corp that investors may wish to consider to help them evaluate ANGN as an investment opportunity.
Angion Biomedica: Selling At Cash ValueWithin any important issue, there are always aspects no one wishes to discuss.”― George Orwell Today, we take our first in-depth look at a small biotech developmental firm that went public just less than a year ago, but is already deep in 'Busted IPO' territory. It popped up on our... |
Angion Biomedica (ANGN) Investor Presentation - SlideshowNo summary available. |
Trade Alert: The President Of Angion Biomedica Corp. (NASDAQ:ANGN), Jay Venkatesan, Has Just Spent US$730k Buying 24% More SharesThose following along with Angion Biomedica Corp. ( NASDAQ:ANGN ) will no doubt be intrigued by the recent purchase of... |
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries, today provided a corporate update and announced |
H.C. Wainwright Sticks to Its Buy Rating for Angion Biomedica (ANGN)H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Angion Biomedica (ANGN – Research Report) today and set a price target of $50.00. The company's shares closed last Friday at $2.90, close to its 52-week low of $2.28. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Angion Biomedica has an analyst consensus of Strong Buy, with a price target consensus of $21.00. |
ANGN Price Returns
| 1-mo | 17.19% |
| 3-mo | -27.18% |
| 6-mo | -58.33% |
| 1-year | -90.28% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -48.28% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...